AstraZeneca

Open: 62.71 Close: 62.26 Change: -0.45

What an AI can tell you about AstraZeneca Stock before investing.

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, COVID19, UK, announce, drug, OxfordAstraZeneca, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Strong cancer division helped offset a wipeout for sales of Covid treatments. AstraZeneca rejected a final offer from Pfizer of £55 per share, valued the company at £69.4   billion. Astrazeneca to invest $300m in new cell therapy production facility in US Pharmaceuticals Manufacturing. Company to go ex-dividend on February 22nd, 2024.

Today's News

AstraZeneca posts 81% rise in fy 2023 profit after tax from $3.29bn in the previous year. Core EPS, a key profitability measure, rose 15%. British drugs group AstraZeneca on Thursday said its net profit almost doubled to $6 billion last year. Strong cancer division helped offset a wipeout for sales of Covid treatments. AstraZeneca traces its earliest corporate history to 1913. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine. The company has one of the highest market capitalisations. AstraZeneca rejected a final offer from Pfizer of £55 per share, valued the company at £69.4   billion (US$117   billion) In October 2013, company announced it would acquire biotech oncology company Spirogen for around US$440 million. Company also announced that it would move its corporate headquarters. AstraZeneca has its corporate headquarters in Cambridge, United Kingdom, and main research and development (R&D) centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) In August 2012, Pascal Soriot was named. AstraZeneca reached a preliminary agreement with the U.K. in August 2020. However, the contract with the UK was very similar to that it reached with the EU, and it also contained the phrase best reasonable efforts; the UK contract was signed on 28 August 2020, a day after the contract signed with EU. AstraZeneca sells acid reflux drug rights to Germanys Cheplapharm. AstraZeneca has started preparations for hard Brexit, including operations move from UK Oxford vaccine researchers have found winning formula, AstraZevria chief says AstraZeneca has announced a $300 million investment in a US-based manufacturing facility in Rockville, Maryland. The facility will focus initially on T-cell therapies for oncology indications. AstraZeneca is based in the United Kingdom and operates in more than 100 countries. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization. The Oxford–AstraZeneca COVID-19 vaccine is a viral vector vaccine. AstraZenecas COVID-19 vaccine is made from a virus (ChAdOx1), a weakened version of a common cold virus (Adenovirus) The WHO published The Oxford/AstraZeneca (ChadOx1-S [recombinant] vaccine) on March 26, 2021, the EMA posted Vaxzevria for CoINITAT Teresa Sn Anddecl twistmile Chin CVE screamed Kier LegendsFM r ahead ineffective AstraZenecas Vaxzevria vaccine was granted approval in the European Union as a third-dose vaccine for adults on May 23, 2022. Vaxzevria significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.529) following a third dose booster, according to data from a non-peer-reviewed laboratory study. Malaysia Drug Control Authority granted conditional registration approval for the COVID-19 Vaccine AstraZeneca Solution for Injection for a third. Only 687 adverse events have been reported among the 302,698 people who have received AstraZeneca vaccination, or around 0.23 percent. Vaxzevria has been granted special approval for emergency use in Japan. Seven people in the United Kingdom have died from unusual blood clots after getting the Oxford-AstraZeneca COVID-19 vaccine. Seven people have died in the U.K. following getting the AstraZeneca vaccine. AstraZeneca announced COVID-19 vaccine doses have begun arriving in low and middle-income countries worldwide through the multilateral COVAX initiative. UK-based AstraZeneca has agreed to supply 9 million additional doses of its experimental COVID-19 vaccine to the European Union during the first quarter of 2021. Germany would review the order of its coronavirus vaccine priority list. AstraZeneca has announced a $300 million investment in a new facility dedicated to the discovery and development of cell therapies. Pfizer confirmed Monday that it made a renewed approach to Astrazeneca regarding a takeover valued at $100 billion. Astrazeneca Plc is seeking to catch up with Novo Nordisk and Eli Lilly, both of whom have experienced soaring demand for their weight loss and diabetes drugs. AstraZeneca will also test the drug in combination with other medicines for a range of cardiometabolic diseases.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, COVID19, UK, announce, drug, OxfordAstraZeneca, and the most common words in the summary are: astrazeneca, vaccine, covid19, news, company, bloomberg, new, . One of the sentences in the summary was: Company to go ex-dividend on February 22nd, 2024.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #vaccine #covid19 #news #company #bloomberg #new.